ENMD-2076

N/A

Report date: 2023/06/30 20:00:34
NME

Base Information

Drug NameENMD-2076
Drug Alias NameMKC-1693ENMD-981693ENMD-2076
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase Aurora-A inhibitorsTyrosine-protein kinase receptor FLT3 inhibitorsVascular endothelial growth factor receptor 2 inhibitors +[9] 
TargetsSerine/threonine-protein kinase Aurora-ATyrosine-protein kinase receptor FLT3Vascular endothelial growth factor receptor 2 +[9] 
Therapy Area/IndicationsFallopian Tube NeoplasmsHematologic NeoplasmsOvarian Neoplasms +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesMainland China
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaPending
Originator CompaniesCasi Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCasi Pharmaceuticals IncAaipharma Services CorpUniversity Health Network (Uhn) +[4] 
Active IndicationsN/A
Inactive IndicationsFallopian Tube NeoplasmsHematologic NeoplasmsOvarian Neoplasms +[10] 

Other Information

ATC CodeN/A
Related LinksN/A